US Patent 10,174,017: Scope, Claim Architecture, and US Landscape
What does US Drug Patent 10,174,017 actually claim?
US Patent 10,174,017 covers a small-molecule chemical series defined by Formula (VI) plus pharmaceutically acceptable salts, and it ties that chemistry to eye indications (including glaucoma and dry eye) and to a cellular kinase-modulation mechanism. Independent claim coverage is anchored on the Formula (VI) subset where R4 is methyl and n is 2, which narrows the chemical universe to a specific structural slice.
Core chemical limiter (present throughout)
Across the independent claim set, the active subject matter is:
- Compound of Formula (VI) (or salt)
- R4 = methyl
- n = 2
That means infringement risk and licensing leverage concentrate on compounds that match this structural definition, not on the broader Formula (VI) genus without those constraints.
What are the key claim positions and how broad are they?
The claims read like a typical pharma “chemistry + formulation + method” bundle, with additional downstream method-of-use language that ranges from targeted ocular dosing to broader kinase activity modulation.
Claim 1 (chemical composition claim; narrow structural subset)
- Claim 1: A compound of Formula (VI) (or salt) with R4 is methyl and n is 2.
Scope: This is the primary right on the structure. It is not limited to any route, indication, or formulation. Practically, it is limited by the exact structural feature set in the Formula (VI) plus the stated parameters.
Claim 2 (specific embodiment; explicit named compound)
- Claim 2: Claim 1 compound wherein the compound is:
- 4-(3-amino-1-(isoquinolino-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate (or salt)
Scope: This is a direct call-out of the flagship molecule within the restricted Formula (VI) subset. It reduces ambiguity for enforcement and helps distinguish this patent from related family members that may cover different parameter combinations.
Claims 3-7 (composition and formulation; carrier-limited dosing window)
- Claim 3: A composition comprising the compound of claim 1.
- Claim 4: Claim 3 where the compound is the named molecule (or salt).
- Claim 5: A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
- Claim 6: Claim 5 with the named compound (or salt).
- Claim 7: Claim 6 where the carrier is saline buffered to pH about 5.5 to about 6.5.
Scope gradation:
- Claims 3-6 capture general formulations with acceptable carriers.
- Claim 7 tightens to a defined buffer pH window (5.5 to 6.5), which can matter for both product design-around and formulation differentiation in the regulatory product.
Claims 8-14 (method for treating eye disease; broad disease list)
- Claim 8: Treat an eye disease by administering an effective amount of Formula (VI) (R4 methyl, n=2) or salt.
- Claim 9: Specifies the named molecule.
- Claim 10: Eye disease comprises glaucoma.
- Claim 11: Eye disease comprises neurodegenerative eye disease.
- Claim 12: Eye disease comprises dry eye.
- Claim 13: Eye disease comprises ocular hypertension.
- Claim 14: Administration is topical to the eye.
Scope: This is strong for ocular product concepts. It is not limited to one mechanism-of-action in the claim text; it is limited primarily by compound identity and route in dependent claims.
Claims 15-21 (IOP reduction; topical method explicitly claimed)
- Claim 15: Reduce intraocular pressure (IOP) by administering the Formula (VI) compound (R4 methyl, n=2) or salt.
- Claim 16: Named compound.
- Claim 17: Subject suffering from glaucoma.
- Claim 18: Named compound in glaucoma context.
- Claim 19: Subject suffering from ocular hypertension.
- Claim 20: Named compound in ocular hypertension context.
- Claim 21: Administration is topical.
Scope: This claim set overlaps heavily with conventional glaucoma competitive spaces, giving two enforcement hooks:
1) general eye-disease treatment; and
2) a specific physiological endpoint (IOP reduction).
Claims 22-31 (kinase activity modulation via cell contact; route split)
- Claim 22: Modulate kinase activity in a cell by contacting the cell with an amount effective to modulate kinase activity of the Formula (VI) compound.
- Claim 23: Named compound.
- Claim 24: Cell is in a subject.
- Claim 25: Subject is human.
- Claim 26: Administration is topical.
- Claim 27: Administration is systemic.
- Claims 28-31: Human subjects suffering from glaucoma, neurodegenerative eye disease, dry eye, or ocular hypertension, respectively.
Scope: Claim 22 introduces a mechanistic layer that can be used even when the clinical endpoint language is contested. The dependent claims also span both topical and systemic dosing.
How does claim breadth compare across chemistry, formulation, and methods?
A practical way to value this patent for enforcement and freedom-to-operate is to compare what each claim category covers:
| Claim category |
Coverage axis |
How constrained |
What it protects well |
| Chemistry (Claim 1) |
Structure |
R4=methyl, n=2 |
Direct infringement by matched structure |
| Named compound (Claim 2) |
Explicit embodiment |
Exact named molecule in the subset |
Cleaner enforcement vs genus-only families |
| Formulation (Claims 3-6) |
Carrier presence |
“pharmaceutically acceptable carrier” |
Most product forms using acceptable carriers |
| Buffered carrier (Claim 7) |
Buffer pH |
pH 5.5 to 6.5 |
Potentially narrower but product-relevant enforcement lever |
| Eye disease treatment (Claims 8-14) |
Indication + route |
disease list + topical |
Covers ocular therapeutics with that endpoint framing |
| IOP reduction (Claims 15-21) |
Endpoint |
IOP + topical in dependent |
Strong in glaucoma/ocular hypertension contexts |
| Kinase modulation (Claims 22-31) |
Mechanistic action |
compound + kinase modulation effect; dose route in dependents |
Helps maintain value if clinical labels differ |
Net assessment: Claims 8 and 15 are the most commercially aligned with marketed glaucoma and dry-eye categories, while Claim 22 adds a mechanistic pathway that can expand how the patent is argued in disputes.
What is the enforcement “sweet spot” within the claim set?
The strongest convergence of chemical specificity and commercial relevance sits at:
- The named compound (Claim 2 / Claim 4 / Claim 6 / Claim 9 / Claim 16 / Claim 18 / Claim 20 / Claim 23)
- in ocular treatment and IOP reduction contexts (Claims 10, 12-13, 17, 19)
- with topical administration (Claims 14 and 21; also Claim 26 as dependent under kinase modulation)
This cluster tends to map directly onto product development choices: compound selection, ocular dosing route, and the clinical rationale used in labeling and publications.
What does the pH-limited formulation claim imply for product design-around?
- Claim 7: requires saline buffered to pH ~5.5 to ~6.5 for that particular formulation embodiment.
For a competitor, pH range can be a meaningful design parameter when the carrier otherwise falls into “pharmaceutically acceptable” broad territory. But it does not eliminate exposure from Claims 3-6 and 5 if those do not require pH specification. In other words:
- Claim 7 is narrower (pH-limited),
- while the earlier formulation claims are broader (carrier-agnostic beyond “pharmaceutically acceptable”).
The practical implication is that pH alone may not be sufficient to avoid infringement if the product still contains the same compound as defined by Claim 1/2.
What does the kinase-activity claim add to the patent’s leverage?
Claim 22 creates a separate claim pathway not strictly tied to:
- a particular disease label,
- or even the IOP endpoint, in its independent form.
Instead, it focuses on contacting a cell with an effective amount to modulate kinase activity. Dependent claims then tether the dosing context back to human subjects and topical vs systemic administration, and reintroduce the ocular disease list.
For litigation strategy, mechanistic claims can:
- broaden argument structure beyond the clinical condition named in the labeling, and
- enable discussion of pharmacology and target engagement if the defendant argues non-infringement of the ocular-disease framed methods.
How does this claim set position within the US patent landscape?
US Drug Patent protection for a specific marketed mechanism typically appears as:
- a primary composition-of-matter claim (or narrow subset) and
- a set of method-of-use and formulation claims tailored to the therapeutic area.
In this case, the patent is positioned to cover a pipeline from:
1) chemical series (Formula VI subset)
2) specific named embodiment (the named benzyl 2,4-dimethylbenzoate salt/structure)
3) ocular therapeutic use (glaucoma, ocular hypertension, dry eye, neurodegenerative eye disease)
4) IOP reduction
5) kinase modulation
This is consistent with a patent family designed to maintain value even as clinical development changes between endpoints or patient populations, since the claims include both physiological (IOP) and mechanistic (kinase modulation) hooks.
Claims-by-Claim map to landscape “risk areas” (what to watch)
Chemistry / API risk
- Anything using a compound that matches Formula (VI), R4=methyl, n=2
- Enforcement focus increases if the candidate is the explicitly named compound:
4-(3-amino-1-(isoquinolino-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate
Formulation risk
- Most topical ocular formulations using a pharmaceutically acceptable carrier are exposed under Claims 5-6.
- If a product uses saline buffered to pH 5.5-6.5, it is directly exposed under Claim 7.
Clinical and labeling risk
- Any program positioning as:
- glaucoma treatment,
- ocular hypertension treatment,
- dry eye treatment,
- neurodegenerative eye disease treatment,
using the claimed compound, and especially with topical administration, runs into Claims 8-14 and 15-21.
Mechanism-of-action risk
- Programs describing that the compound modulates kinase activity in cells and presenting data tied to human dosing contexts can draw into Claims 22-31, including topical/systemic dosing pathways.
Key Takeaways
- US 10,174,017 is anchored on a narrow chemical slice of Formula (VI) with R4=methyl and n=2, supported by a named embodiment (4-(3-amino-1-(isoquinolino-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate).
- The patent’s practical enforcement strength comes from ocular method claims covering glaucoma, ocular hypertension, dry eye, and neurodegenerative eye disease, including topical administration and IOP reduction.
- Formulation coverage is broad through “pharmaceutically acceptable carrier” claims (and includes a narrower buffer pH 5.5-6.5).
- The kinase modulation claim expands leverage beyond endpoint-based disputes and supports mechanistic enforcement strategies.
- The highest-risk zone for competitors is the overlap of: same compound identity + ocular route (topical) + glaucoma/IOP or dry-eye/neurodegenerative framing + kinase target engagement narratives.
FAQs
1) Which claim is the core protection for the chemical entity?
Claim 1 protects the Formula (VI) compound (or salt) with R4=methyl and n=2.
2) Does the patent cover the named compound specifically?
Yes. Claim 2 specifies 4-(3-amino-1-(isoquinolino-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate (or salt).
3) Are ocular methods limited to topical dosing?
No. Topical administration is explicitly claimed in dependents (Claim 14 and Claim 21), while the kinase-modulation portion explicitly covers both topical (Claim 26) and systemic (Claim 27) routes.
4) What formulations are most directly captured?
The patent covers pharmaceutical compositions with a pharmaceutically acceptable carrier (Claims 5-6) and a specific buffered saline embodiment (Claim 7, pH about 5.5 to 6.5).
5) Is IOP reduction protected separately from glaucoma treatment?
Yes. Claims 15-21 protect a method for reducing intraocular pressure, including glaucoma and ocular hypertension contexts, with topical administration specified in Claim 21.
References
- US Patent 10,174,017 (claim set as provided in prompt).
